1197469
Last Update Posted: 2012-11-06
Recruiting has ended
All Genders accepted | 35 Years-85 Years |
120 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.
Eligibility
Relevant conditions:
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov